Back to Agenda
RWE Supporting HTA/Payers Determine the Value of Highly Innovative Medicines
Session Chair(s)
Sophie Schmitz
Managing Partner, P4A Partners for Access, Netherlands
RWE Supporting HTA/Payers Determine the Value of Highly Innovative Medicines
Learning Objective : - Share latest insights from the RWE4Decisions payer-led learning network - Discuss how transparency of RWE generation and evaluation can be improved - Explore how partnerships within and across stakeholders can be encouraged to align RWD requirements
Speaker(s)
Sophie Schmitz
Managing Partner, P4A Partners for Access, Netherlands
Life Cycle of Real World Evidence Generation to Help HTA/Payers Determine the Value of Highly Innovative Medicines
Charles Alessi
Independent Expert, FT3, Belgium
Perspective Matters When Assessing the Value of Precision Medicine
Philippe Page, DRSC
Head of Research Council, Trustee, The Human Colossus Foundation, Switzerland
Data Design Principles for Value Exchange in Complex, Multi-Stakeholder Environments
Alexander Natz, JD
Secretary General, European Confederation of Pharmaceutical Entrepreneurs, Belgium
Challenges of Developing Robust RWE Studies for 27 Member States
Have an account?